Intest Res.  2017 Jan;15(1):124-129. 10.5217/ir.2017.15.1.124.

Metronidazole-induced encephalopathy in a patient with Crohn's disease

• Kim J
• Chun J
• Park JY
• Hong SW
• Lee JY
• Kang JW
• Hwang S
• Ko SB
• Im JP
• Kim JS

• KMID: 2368495
• DOI: http://doi.org/10.5217/ir.2017.15.1.124

Abstract

Metronidazole is a widely used antibiotic for the treatment of anaerobic bacterial infections. Metronidazole-induced encephalopathy (MIEP) is a rare but potentially reversible disease. The mechanism of MIEP remains unclear, and differences in the neurotoxic effects of oral versus intravenous (IV) metronidazole administration have not yet been determined. We report the case of a Crohn's disease (CD) patient who experienced encephalopathy immediately after a single IV dose of metronidazole following long-term exposure to the oral form of the drug. The 64-year-old man with intractable CD experienced a sudden change in mental status, aphasia, and muscle weakness after IV administration of metronidazole. He had previously taken metronidazole orally for 13 years and received intermittent IV metronidazole treatments for CD exacerbation. Brain magnetic resonance imaging (MRI) showed high-intensity signals in the bilateral medial thalamus and the midbrain and pontine tegmentum on fluid-attenuated inversion recovery images. After discontinuation of metronidazole, the high-intensity brain MRI signals resolved and the patient's mental status dramatically improved; however, the patient exhibited mild cognitive dysfunction 2 months after the onset of encephalopathy.

Keyword

Metronidazole; Drug side effects; Metabolic encephalopathy; Crohn disease

MeSH Terms

Aphasia
Bacterial Infections
Brain
Brain Diseases*
Brain Diseases, Metabolic
Crohn Disease*
Drug-Related Side Effects and Adverse Reactions
Humans
Magnetic Resonance Imaging
Mesencephalon
Metronidazole
Middle Aged
Muscle Weakness
Pontine Tegmentum
Thalamus
Metronidazole

Figure

• 

  Fig. 1 Abdominal CT finding. CT shows a large enterocutaneous fistula in the middle portion of the abdomen (arrowheads).

• 

  Fig. 2 Brain MRI findings. Fluid-attenuated inversion recovery MRI shows high-intensity lesions in the bilateral medial thalamus (A), midbrain tegmentum (B), pontine tegmentum (C), fourth ventricle and dentate nucleus (D), and subcortical white matter (E) (arrows).

• 

  Fig. 3 Follow-up brain MRI findings. MR images obtained 7 days after metronidazole discontinuation. A fluid-attenuated inversion recovery image shows the improvement of lesions in the bilateral medial thalamus (A, B); midbrain tegmentum (C); pontine tegmentum, fourth ventricle, and dentate nucleus (D); and subcortical white matter (E).

• 

  Fig. 4 Serial results of the Glasgow coma scale (GCS) and total bilirubin testing after cessation of metronidazole (MTZ) treatment. IV, intravenous; tid, three times a day; qd, every day; TPN, total parenteral nutrition.

Reference

1. Kim DH, Cheon JH, Park JJ, et al. Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease. Gut Liver. 2013; 7:58–65. PMID: 23423699.

2. Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010; 50(Suppl 1):S16–S23. PMID: 20067388.

3. Han DS. Current status and prospects of intestinal microbiome studies. Intest Res. 2014; 12:178–183. PMID: 25349591.

4. Kim JM. Antimicrobial proteins in intestine and inflammatory bowel diseases. Intest Res. 2014; 12:20–33. PMID: 25349560.

5. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999; 36:353–373. PMID: 10384859.

6. Groothoff MV, Hofmeijer J, Sikma MA, Meulenbelt J. Irreversible encephalopathy after treatment with high-dose intravenous metronidazole. Clin Ther. 2010; 32:60–64. PMID: 20171413.

7. Boyce EG, Cookson ET, Bond WS. Persistent metronidazole-induced peripheral neuropathy. DICP. 1990; 24:19–21. PMID: 2154078.

8. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996; 91:328–332. PMID: 8607501.

9. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011; 34:241–247. PMID: 21996645.

10. Patel K, Green-Hopkins I, Lu S, Tunkel AR. Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. Int J Infect Dis. 2008; 12:e111–e114. PMID: 18511323.

11. Seok JI, Yi H, Song YM, Lee WY. Metronidazole-induced encephalopathy and inferior olivary hypertrophy: lesion analysis with diffusion-weighted imaging and apparent diffusion coefficient maps. Arch Neurol. 2003; 60:1796–1800. PMID: 14676060.

12. Idkaidek NM, Najib NM. Enhancement of oral absorption of metronidazole suspension in humans. Eur J Pharm Biopharm. 2000; 50:213–216. PMID: 10962229.

13. Manafi A, Panjehshahin MR, Saravi MG, Emami SA, Forootan SK. Reduced bioavailability of oral metronidazole in postoperative ileus. Iran Red Crescent Med J. 2007; 9:129–132.

14. Yamamoto T, Abe K, Anjiki H, Ishii T, Kuyama Y. Metronidazole-induced neurotoxicity developed in liver cirrhosis. J Clin Med Res. 2012; 4:295–298. PMID: 22870180.

15. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology. 2007; 45:230–241. PMID: 17187426.

16. Zuccoli G, Pipitone N, Santa Cruz D. Metronidazole-induced and Wernicke encephalopathy: two different entities sharing the same metabolic pathway? AJNR Am J Neuroradiol. 2008; 29:E84. PMID: 18566011.

17. Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry. 1986; 49:341–345. PMID: 3701343.

18. Manzo G, De Gennaro A, Cozzolino A, Serino A, Fenza G, Manto A. MR imaging findings in alcoholic and nonalcoholic acute Wernicke's encephalopathy: a review. Biomed Res Int. 2014; 2014:503596. PMID: 25050351.

19. Kim E, Na DG, Kim EY, Kim JH, Son KR, Chang KH. MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol. 2007; 28:1652–1658. PMID: 17885234.

20. Zuccoli G, Pipitone N. Neuroimaging findings in acute Wernicke's encephalopathy: review of the literature. AJR Am J Roentgenol. 2009; 192:501–508. PMID: 19155417.

21. Shin IS, Seok H, Eun YH, et al. Wernicke's encephalopathy after total parenteral nutrition in patients with Crohn's disease. Intest Res. 2016; 14:191–196. PMID: 27175122.

22. Yoon SM. Micronutrient deficiencies in inflammatory bowel disease: trivial or crucial. Intest Res. 2016; 14:109–110. PMID: 27175110.